DelveInsight’s, “Graft versus host disease Pipeline Insight 2023” report provides comprehensive insights about 60+ Graft versus host disease companies and 65+ pipeline drugs in the Graft versus host disease pipeline landscape. It covers the Graft versus host disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Graft versus host disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Graft versus Host Disease Pipeline Report

• DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for Graft versus host disease treatment.
• The leading companies working in the Graft versus host disease Market include AltruBio, Syndax Pharmaceutical, MaaT Pharma, Medac, CSL Behring, Takeda, Oncoimmue, ElsaLys Biotech, Xenikos, Incyte Corporation, Jazz Pharmaceutials, Kadmon Corporation, Regimmune Corporation, Medsenic, AstraZeneca, Biogen, Pfizer, Equillium, GlaxoSmithKline, Amgen, CTI BioPharma, Bristol-Myers Squibb, Synthetic Biologics, Evive Biotech, Orca Bio, Novartis, Roche, Millennium, and others.
• Promising Graft versus host disease Pipeline Therapies in the various stages of development include Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.
• August 2023: SCRI Development Innovations LLC announced a study of phase 2 clinical trials for Itacitinib. This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months. The purpose of this study is to find out if itacitinib in combination with corticosteroids or other immunosuppressive therapies is safe and effective in people with cGVHD.
• September 2023: Equillium announced a study of phase 3 clinical trials for Itolizumab and EQ001. This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids.

 

Request a sample and discover the recent advances in Graft versus host disease Treatment Drugs @ Graft versus host disease Pipeline Report

 

In the Graft versus host disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Graft versus host disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Graft versus host disease (GVHD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Graft versus host disease Overview

Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient.

 

Find out more about Graft versus host disease Therapeutics Assessment @ Graft versus host disease Preclinical and Discovery Stage Products

 

Graft versus host disease Emerging Drugs Profile

• MaaT013: MaaT Pharma
• MC0518: Medac
• SNDX-6532: Syndax Pharmaceutical
• Neihulizumab: AltruBio

 

Graft versus host disease Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the Graft versus host disease therapies. The Graft versus host disease companies which have their drug candidates in the most advanced stage, i.e Phase III include MaaT Pharma.

 

Learn more about the emerging Graft versus host disease Pipeline Therapies @ Graft versus host disease Clinical Trials Assessment

 

Scope of the Graft versus host disease Pipeline Report

• Coverage- Global
• Graft versus host disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Graft versus host disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Graft versus host disease Companies- AltruBio, Syndax Pharmaceutical, MaaT Pharma, Medac, CSL Behring, Takeda, Oncoimmue, ElsaLys Biotech, Xenikos, Incyte Corporation, Jazz Pharmaceutials, Kadmon Corporation, Regimmune Corporation, Medsenic, AstraZeneca, Biogen, Pfizer, Equillium, GlaxoSmithKline, Amgen, CTI BioPharma, Bristol-Myers Squibb, Synthetic Biologics, Evive Biotech, Orca Bio, Novartis, Roche, Millennium, and others.
• Graft versus host disease Pipeline Therapies- Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

 

Dive deep into rich insights for new drugs for Graft versus host disease treatment, Visit @ Graft versus host disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Graft versus host disease Executive Summary
3. Graft versus host disease: Overview
4. Graft versus host disease Pipeline Therapeutics
5. Graft versus host disease Therapeutic Assessment
6. Graft versus host disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. MaaT013: MaaT Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SNDX-6532: Syndax Pharmaceutical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Neihulizumab: AltruBio
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Graft versus host disease Key Companies
21. Graft versus host disease Key Products
22. Graft versus host disease- Unmet Needs
23. Graft versus host disease- Market Drivers and Barriers
24. Graft versus host disease- Future Perspectives and Conclusion
25. Graft versus host disease Analyst Views
26. Graft versus host disease Key Companies
27. Appendix

 

For further information on the Graft versus host disease pipeline therapeutics, reach out to Graft versus host disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking